Gilead Sciences announces positive results from Veklury and obeldesivir trials Gilead Sciences, announced positive results from several COVID-19 clinical and real-world evidence studies presented at ECCMID. A Phase 3 clinical study demonstrated that Veklury (remdesivir) was generally well tolerated in people with moderate to severe renal impairment. Additional data includes a retrospective real-world study which […]

Shionogi demonstrates efficacy of cefiderocol against difficult-to-treat Gram-negative bacterial infections At ECCMID 2023, Osaka, Japan-based Shionogi announced key data for cefiderocol, an innovative siderophore cephalosporin, including new real-world evidence demonstrating its efficacy against some of the most difficult-to-treat Gram-negative bacterial infections.

Influential ECCMID 2023 sees numerous scientific presentations The 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) took place in Copenhagen, Denmark, 15-18 April 2023. With around 14,000 professional attendees ECCMID is the largest international meeting of clinical microbiologists and infectious diseases specialists. The event included a comprehensive scientific programme, an industry programme and […]

by Dr Jacqueline Gosink Biomarkers and preanalytics in Alzheimer’s disease Analysis of biomarkers such as amyloid-beta peptides and tau proteins in cerebrospinal fluid (CSF) is nowadays a core criterion in Alzheimer’s disease diagnostics. Test methods such as ELISA and chemiluminescence immunoassay enable robust and reproducible measurement of the analytes in patient CSF samples. Recommendations for […]

by Professor Stephen Bustin   Remodelling qPCR as a tool for molecular diagnostics PCR is an incredibly powerful tool in the field of molecular diagnostics, and its current role is embedded in the clinical laboratory where it is indispensable for non-time-critical routine testing. However, point-of-care testing via lateral flow devices, as seen in the recent […]